Research summary
Research HubLL-37
Clinical — 10 studies
LL-37 is a human antimicrobial peptide studied for its role in innate immunity and wound healing research.
Being studied for
- Antimicrobial activity research
- Wound healing
- Innate immune defense mechanisms
Published Research
Evidence profile
Preclinical, with limited uncontrolled human reports
10 cited publications
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Additional indexed literature (10)
- Clinical · Mechanistic studyCathelicidin LL-37 Expression in Human Breast Implant Capsules
Segreto F et al. · Plastic and reconstructive surgery · 2024 · PMID 37220260
- Clinical · Mechanistic studySalivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV
Seminario AL et al. · Biomedicine hub · 2024 · PMID 38287973
- Clinical · Mechanistic studySalivary and serum cathelicidin LL-37 levels in subjects with rheumatoid arthritis and chronic periodontitis
Cheah CW et al. · International journal of rheumatic diseases · 2020 · PMID 32743970
- Preclinical · Mechanistic studyCathelicidin LL-37-ApoB-100 interaction promotes LDL clearance and attenuates cholesterol accumulation in the liver
Fang Y et al. · Science China. Life sciences · 2026 · PMID 40971038
- Preclinical · Mechanistic studyCathelicidin LL-37-Induced Transcriptome of Human Keratinocyte Identifies Chemokine CXCL10 Link to T-Cell-Mediated Rosacea Pathogenesis through Jak1/STAT1 Pathway
Ansari AW et al. · The Journal of investigative dermatology · 2026 · PMID 40835085
- Preclinical · Mechanistic studyCathelicidin LL-37 promotes wound healing in diabetic mice by regulating TFEB-dependent autophagy
Xi L et al. · Peptides · 2024 · PMID 38423213
- Preclinical · Mechanistic studyVitamin D triggers hCAP18/LL-37 production: Implications for LL-37-induced human osteoblast cytotoxicity
Aidoukovitch A et al. · Biochemical and biophysical research communications · 2024 · PMID 38642493
- Preclinical · Mechanistic studyHuman Cathelicidin, LL-37 a potential antiviral therapeutic for Rift Valley Fever Virus in Egypt
Ahmed EM et al. · Cellular and molecular biology (Noisy-le-Grand, France) · 2024 · PMID 39262269
- Preclinical · Mechanistic studyCathelicidin (LL-37) causes expression of inflammatory factors in coronary artery endothelial cells of Kawasaki disease by activating TLR4-NF-κB-NLRP3 signaling
Si F et al. · Immunity, inflammation and disease · 2023 · PMID 37773705
- Preclinical · Mechanistic studyEfficacy of Cathelicidin LL-37 in an MRSA Wound Infection Mouse Model
Simonetti O et al. · Antibiotics (Basel, Switzerland) · 2021 · PMID 34680791
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Cobalt Peptides material. Citations verified against PubMed on 2026-08-09.
Notice
All information on this page is provided strictly for laboratory research and educational purposes only.